Figure 1.
![Figure 1. PFS. Kaplan-Meier estimates of PFS of (A) all patients and subgroups stratified by: (B) TP53 aberration (absent vs present), (C) prior treatment (RR CLL vs TN), (D) Rai stage (I/II vs III/IV), (E) B2M (≤4 mg/L vs >4 mg/L), and (F) IGHV mutational status (mutated IGHV [M] vs unmutated IGHV [U]). Among patients with TP53 aberration (n = 53), subgroups are further divided by: (G) prior treatment (RR vs TN), (H) Rai stage (I/II vs III/IV), and (I) B2M (≤4 mg/L vs >4 mg/L).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/129/11/10.1182_blood-2016-06-719294/4/blood719294f1.jpeg?Expires=1736048127&Signature=heEqgyRGlj~gRm270imQeWqrqg4dphQgBJusrUZ708othSvOZR49vLFulRLpw0I61fOeYob7a9XzUkkjvRqlWAkirnKRfHLATYIizXYWmIoY-3IQx4JaNwRngmgpjQiz-d4jBh9F7XQxTJjggCqCfIEd9EyT--iBdvnO7hx6U4L1YRUckxZwqRzMMO94pp-zmpNcCdN6HvLhRQ4e1wOQpgty-LZR8Gv~63-2zalwCWcaUR44S~BySTA5eh~9im8yojyJPGs5esdVxUojWpMkdemksq7z2hVtx6kqvzN-y7Ftbd6OGUfJST7AR7Oridu8J2Gh6un6~pIlBBN7piDrlw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
PFS. Kaplan-Meier estimates of PFS of (A) all patients and subgroups stratified by: (B) TP53 aberration (absent vs present), (C) prior treatment (RR CLL vs TN), (D) Rai stage (I/II vs III/IV), (E) B2M (≤4 mg/L vs >4 mg/L), and (F) IGHV mutational status (mutated IGHV [M] vs unmutated IGHV [U]). Among patients with TP53 aberration (n = 53), subgroups are further divided by: (G) prior treatment (RR vs TN), (H) Rai stage (I/II vs III/IV), and (I) B2M (≤4 mg/L vs >4 mg/L).
